INDV1 Stock Chart & Stats
$600.10
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$600.10 - $645.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$78.56B
Enterprise Value$4.57B
Total Cash (Recent Filing)$305.00M
Total Debt (Recent Filing)$501.00M
Price to Earnings (P/E)9.6
Beta-0.02
Next Earnings
Mar 04, 2027EPS Estimate
18.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.66
Shares Outstanding118,031,940
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-45.77
Price to Sales (P/S)3.62
P/FCF Ratio-47.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$867.81Price Target Upside― Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)79.03
Revenue Forecast (FY)$24.93B
Bulls Say, Bears Say
Bulls Say
SUBLOCADE Growth And ProtectionSUBLOCADE combines strong recent growth, leading market share, record new patient starts, and a long patent runway. These features support durable pricing power and patient retention while limiting near-term generic pressure, making the product a credible multi-year foundation for revenue and cash generation.
Improved ProfitabilityThe sharp improvement in profitability indicates that Indivior is converting product growth into substantial operating earnings rather than relying only on higher sales. Sustained margin expansion can strengthen internal funding capacity, support investment in commercialization, and improve resilience across the business cycle.
Merger Scale And SynergiesCombining Indivior with Supernus would broaden the CNS portfolio, increase commercial scale, and add identified cost savings targeted within 12 months. A larger platform may diversify growth opportunities and improve operating leverage, while the projected synergy plan provides a concrete path to additional profitability.
Bears Say
Negative Shareholders’ EquityNegative equity weakens the balance sheet’s financial cushion and makes conventional leverage measures less informative. Combined with debt, it leaves less flexibility to absorb earnings or cash-flow setbacks, fund unexpected needs, or pursue growth without increasing financial pressure on the company.
Volatile Cash GenerationInconsistent operating and free cash flow reduces confidence that reported earnings will reliably translate into funds available for debt reduction, investment, or shareholder returns. The sharp variation across periods makes planning more difficult and increases sensitivity to any slowdown in product performance.
SUBLOCADE Concentration And Merger ExecutionThe combined company would depend heavily on one product while simultaneously integrating two commercial organizations. Any slowdown in SUBLOCADE adoption, payer access, or market share could have an outsized effect, and execution demands may delay the realization of expected strategic and cost benefits.
Indivior News
INDV1 FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was $600.10 and its highest was $645.80 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is $78.56B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Mar 04, 2027 which is in 124 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Oct 29, 2026. The company reported $24.924 earnings per share for the quarter, beating the consensus estimate of $20.034 by $4.89.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 18.62.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 118,031,940 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of $24.924 in its last earnings report, beating expectations of $20.034. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in MX:INDV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indivior Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$867.81 (― Upside)
$867.81 (― Upside)
Blogger Sentiment
Bullish
MX:INDV1 Sentiment 86%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
39.65%
12-Months-Change
Fundamentals
Return on Equity
-352.94%
Trailing 12-Months
Asset Growth
-15.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Indivior PLC
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
INDV1 Company Deck
INDV1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presents a constructive and optimistic view of the merger: management emphasized scale, a diversified portfolio (~$2.2B pro forma revenue), strong pro forma profitability (adjusted EBITDA $888M; ~41% margin), and $125M of near-term cost synergies, while retaining balance sheet strength and highlighting SUBLOCADE as a durable, large growth driver (~44% of revenue) supported by IP and commercial momentum. Noted risks include revenue concentration in SUBLOCADE, increased pro forma net debt (~$878M, ~1x leverage), absence of quantified revenue synergies, and standard integration and regulatory execution risks. On balance, the positives (scale, margins, synergies, product durability) outweigh the lowlights.View all MX:INDV1 earnings summaries